Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIF7KG)

• Drug Name: PMID27977313-Compound-29 Drug Info
• Cross-matching ID:
  PubChem CID: 436058
  CAS Number: CAS 116218-49-6
  TTD Drug ID: DMIF7KG
  ACDINA Drug ID: D01322

Molecule-Related Drug Atlas

Drug(s) Targeting Cytoplasmic thioredoxin reductase (TXNRD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fotemustine	DMV62ED	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Spermidine	DMVJNFI	Plaque psoriasis	EA90.0	Phase 3	[3]
Golden phosphorous acetyletic compound 2	DMYJ15A	N. A.	N. A.	Patented	[1]
Terpyridineplatinum(II) complexe 3	DM54EFD	N. A.	N. A.	Patented	[1]
Terpyridineplatinum(II) complexe 4	DMOV86T	N. A.	N. A.	Patented	[1]
Golden phosphorous acetyletic compound 1	DMVAKUI	N. A.	N. A.	Patented	[1]
Acyl oxymethyl acrylamide ester derivative 1	DMXTUE1	N. A.	N. A.	Patented	[1]
PMID27977313-Compound-18	DMIA3GH	N. A.	N. A.	Patented	[1]
Triazole gold complexe 1	DMCWES7	N. A.	N. A.	Patented	[1]
4-aryl quinol derivative 2	DM7TW5Z	N. A.	N. A.	Patented	[1]

Drug(s) Affected By Coagulation factor X (F10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[4]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[5]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[6]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[7]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[8]
Estriol	DMOEM2I	Hormone deficiency	5A61.1	Approved	[9]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[10]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[11]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[12]
Ardeparin	DMYRX8B	Deep vein thrombosis	BD71	Approved	[13]

Drug(s) Affected By Histidine-rich glycoprotein (HRG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[7]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[5]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[17]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[18]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[19]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[20]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[11]

Drug(s) Affected By Alpha-2-antiplasmin (SERPINF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[4]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[7]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[21]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[21]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[5]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[22]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[10]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytoplasmic thioredoxin reductase (TXNRD1)	TTR7UJ3	TRXR1_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alpha-2-antiplasmin (SERPINF2)	OTZGAF8B	A2AP_HUMAN	Drug Response	[2]
Apolipoprotein B (APOB)	OTS88GMA	APOB_CHICK	Drug Response	[2]
Coagulation factor X (F10)	OT2BLK17	FA10_HUMAN	Drug Response	[2]
Histidine-rich glycoprotein (HRG)	OTPLUFOG	HRG_HUMAN	Drug Response	[2]
Plasminogen activator (pla)	OT47J5C9	PLA_YERPE	Drug Response	[2]
Very low-density lipoprotein receptor	OTZBTD8C	VLDLR_HUMAN	Drug Response	[2]

References

• [1] Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
• [2] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [3] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [4] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [5] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [6] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [7] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [8] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [9] Vascular complications of long-term oestrogen therapy. Front Horm Res. 1977;5:174-91. doi: 10.1159/000401993.
• [10] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [11] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [12] Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells. Oncol Rep. 2008 Jun;19(6):1627-34.
• [13] Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery. Blood Coagul Fibrinolysis. 1993 Dec;4 Suppl 1:S33-5; discussion S37-8.
• [14] Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9. Oncotarget. 2016 Dec 13;7(50):83359-83377.
• [15] Proteomics analysis of the proliferative effect of low-dose ouabain on human endothelial cells. Biol Pharm Bull. 2007 Feb;30(2):247-53. doi: 10.1248/bpb.30.247.
• [16] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [17] Estrogens reduce plasma histidine-rich glycoprotein (HRG) levels in a dose-dependent way. Thromb Haemost. 1995 Mar;73(3):484-7.
• [18] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [19] Effects of olanzapine on serum protein phosphorylation patterns in patients with schizophrenia. Proteomics Clin Appl. 2015 Oct;9(9-10):907-16. doi: 10.1002/prca.201400148. Epub 2015 May 15.
• [20] Prenatal arsenic exposure and shifts in the newborn proteome: interindividual differences in tumor necrosis factor (TNF)-responsive signaling. Toxicol Sci. 2014 Jun;139(2):328-37. doi: 10.1093/toxsci/kfu053. Epub 2014 Mar 27.
• [21] Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment. Chin Med J (Engl). 2000 Mar;113(3):236-40.
• [22] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [23] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.